Indication
Respiratory Syncytial Virus Prevention
3 clinical trials
3 products
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate Efficacy, Safety, Reactogenicity, and Immunogenicity of an Ad26.RSV.preF-based Vaccine in Japanese Adults Aged 60 Years and Older, and Safety, Reactogenicity, and Immunogenicity of the Vaccine in Japanese Adults Aged 20 to 59 Years at High-risk of RSV DiseaseStatus: Terminated, Estimated PCD: 2023-03-20
Clinical trial
A Randomized, Double-blind Phase 3 Study to Compare the Immunogenicity of Clinical Trial Material of an Ad26.RSV.preF-based Vaccine for Phase 3 With Clinical Trial Material Representative of Phase 2b in Adults Aged 60 to 75 YearsStatus: Completed, Estimated PCD: 2022-03-07
Product
Ad26.RSV.preF-based vaccineClinical trial
A Randomized, Double-blind Phase 3 Study to Assess the Immunogenicity and Safety of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75 YearsStatus: Completed, Estimated PCD: 2022-03-28
Product
Ad26.RSV.PreF-based Vaccine